Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study

Tuesday, October 23, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

KENILWORTH, N.J., Oct. 22 Schering-Plough Corporation(NYSE: SGP) today provided an update on the clinical development program forits novel oral thrombin receptor antagonist (TRA). Results from tworandomized, double-blind, placebo-controlled Phase II studies in patients withvascular disease showed that TRA does not increase the rate of major or minorbleeding in patients with acute coronary syndrome or prior ischemic strokewhen added to standard antiplatelet therapy. The trials were conducted inJapan as part of the global registration program for TRA.

"These findings confirm the results of the TRA-PCI Phase II trial, whichwere presented at the American College of Cardiology/i2 Summit earlier thisyear," said Rick Veltri, M.D., group vice president of global clinicalresearch, cardiovascular and metabolic disease, Schering-Plough ResearchInstitute. "We now have three Phase II trials involving a total of more than1,200 patients with vascular disease which consistently demonstrate that TRAis well-tolerated and not associated with an increased rate of bleedingcompared to patients who received standard of care therapy alone."

A secondary objective was to assess whether patients treated with TRA inaddition to standard of care therapy had fewer major adverse cardiovascularevents such as myocardial infarction (heart attack) compared to patientstreated with the standard of care alone. While not powered to establishefficacy, in the acute coronary syndrome study patients undergoingpercutaneous coronary intervention (PCI) treated with TRA had a statisticallysignificant reduction in myocardial infarctions during the periproceduralperiod compared to standard of care alone.

"The significant reduction in periprocedural myocardial infarctions, whichwas not expected given the small size of the study, if confirmed in the largerPhase III studies could demonstrate the potential for TRA as atransformational drug in the treatment of patients with acute coronarysyndrome," added Veltri.

Schering-Plough also announced that TRA has now begun dosing in patientsin the global Phase III development program. The Phase III developmentprogram includes two randomized, double-blind, placebo-controlled trialsenrolling nearly 30,000 patients with vascular disease. The first trial, insecondary prevention, involves approximately 19,500 patients with priormyocardial infarction or stroke, as well as patients with existing peripheralarterial disease. The second trial, in acute coronary syndrome, involvesapproximately 10,000 patients with non-ST segment elevation acute coronarysyndrome.

About the Phase II trials

The Phase II Japanese trial in acute coronary syndrome involved 120patients randomized 4 to 1 to TRA plus standard of care or standard of carealone, and treated for 60 days. Standard of care therapy in this studyincluded aspirin, ticlodipine, and heparin.

The Phase II Japanese trial in patients with prior ischemic strokeinvolved 90 patients randomized 2 to 1 to TRA plus standard of care therapy orstandard of care alone, and treated for 60 days. Standard of care therapyincluded aspirin and thienopyridine at the discretion of investigators.

Overall the incidence of adverse events in these trials was similar acrosstreatment arms.

Full data from the trials will be presented at a future medicalconference.

About the Phase III trials

The Phase III Thrombin Receptor Antagonist in Secondary Prevention ofAtherothrombotic Ischemic Events (TRA 2P-TIMI 50) trial is a multinational,randomized, double-blind, placebo-controlled study in approximately 19,500patients with prior MI or stroke, as well as patients with existingperipheral arterial disease. Patients will be randomized to either placeboplus standard medical care (including aspirin and clopidogrel) or to TRA oncedaily plus standard medical care. This Phase

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store